Page last updated: 2024-11-13
sodium 2,6-dichloroindophenol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23697355 |
| CHEMBL ID | 1476089 |
| CHEBI ID | 948 |
| SCHEMBL ID | 505620 |
| MeSH ID | M0023205 |
Synonyms (72)
| Synonym |
|---|
| AC-18346 |
| 2,5-cyclohexadien-1-one, 2,6-dichloro-4-[(4-hydroxyphenyl)imino]-, sodium salt |
| tillmans' reagent |
| 2,6-dichloro-4-((p-hydroxyphenyl)imino)-2,5-cyclohexadien-1-one sodium salt |
| dichlorphenol-indophenolnatrium |
| ai3-63015 |
| 2,5-cyclohexadien-1-one, 2,6-dichloro-4-((p-hydroxyphenyl)imino)-, sodium salt |
| einecs 210-640-4 |
| sodium, (p-((3,5-dichloro-4-oxo-2,5-cyclohexadien-1-ylidene)amino)phenoxyl)- |
| sodium 4-(3,5-dichloro-4-oxocyclohexa-2,5-dienylideneamino)phenoxide |
| 2,6-dichloroindophenol, sodium salt |
| 2,6-dichlor-n-(4-hydroxyphenyl)-p-benzochinoninum |
| tillman's reagenz |
| indophenol, 2,6-dichloro-, sodium salt |
| nsc 11217 |
| 2,5-cyclohexadien-1-one, 2,6-dichloro-4-((4-hydroxyphenyl)imino)-, sodium salt |
| nsc 17842 |
| 2,6-dichloroindophenol sodium |
| 2,6-dichlorophenol indophenol sodium salt |
| sodium 2,6-dichloroindophenolate |
| nsc-17842 |
| nsc-11217 |
| sodium 2,6-dichloroindophenol |
| 620-45-1 |
| C03822 |
| 2,6-dichlorophenolindophenol sodium salt |
| 2,6-dichloroindophenol sodium salt |
| D-2200 |
| 2,6-dichlorophenol-indo-phenol, sodium salt |
| smr001224408 |
| MLS001359825 |
| D0375 |
| sodium 2,6-dichlorobenzenone-indo-phenol |
| tillman's reagent |
| HMS3065J15 |
| AKOS015964163 |
| AKOS016008668 |
| kad7q8xo1y , |
| 2,5-cyclohexadien-1-one, 2,6-dichloro-4-((4-hydroxyphenyl)imino)-, sodium salt (1:1) |
| unii-kad7q8xo1y |
| 2,6-dichloro-n-(4-hydroxyphenyl)-1,4-benzoquinoneimine sodium salt |
| FT-0610565 |
| AKOS015902643 |
| 2,6-dichloroindophenol sodium [mi] |
| 2,6-dichloro-4-((4-hydroxyphenyl)imino)-2,5-cyclohexadien-1-one sodium salt (1:1) |
| sodium, (p-((3,5-dichloro-4-oxo-2,5-cyclohexadien-1-ylidene)amino)phenoxy)- |
| reagents, tillmans' |
| CHEMBL1476089 |
| 2,6-dichloroindophenol sodium salt hydrate acs |
| SCHEMBL505620 |
| CHEBI:948 , |
| AKOS024285063 |
| J-610028 |
| 4-[(3,5-dichloro-4-oxo-cyclohexa-2,5-dien-1-ylidene)amino]phenolate |
| 1266615-56-8 |
| 2,6-dichlorophenalindephenol sodium salt |
| sodium 4-[(3,5-dichloro-4-oxocyclohexa-2,5-dien-1-ylidene)amino]benzen-1-olate |
| AS-61749 |
| sodium 4-(3,5-dichloro-4-oxocyclohexa-2,5-dienylideneamino)phenolate |
| BCP08658 |
| labotest-bb lt00159816 |
| dcip (sodium) |
| dichlorophenylindophenol sodium;dcpip sodium;indochlorophenol sodium |
| A868572 |
| T71130 |
| DTXSID30889360 |
| sodium;4-[(3,5-dichloro-4-oxocyclohexa-2,5-dien-1-ylidene)amino]phenolate |
| CS-0009915 |
| mfcd00012176 |
| AC-37016 |
| HY-D0018 |
| SY061494 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (27)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 33.9972 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.9462 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 0.8913 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 16.8780 | 0.2239 | 11.2451 | 35.4813 | AID624173; AID720569; AID720584 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 35.4813 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 31.6228 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| P53 | Homo sapiens (human) | Potency | 19.9526 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 15.2393 | 0.3548 | 28.0659 | 89.1251 | AID504847; AID602199; AID602200; AID602201; AID602202 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 35.4813 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 19.9526 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 35.4813 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 (µMol) | 7.0200 | 2.3700 | 54.1398 | 100.0000 | AID588689 |
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 (µMol) | 66.0000 | 4.9100 | 23.7029 | 76.1900 | AID602259; AID602260 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| protein AF-9 isoform a | Homo sapiens (human) | AC50 | 11.4200 | 0.0800 | 8.3802 | 17.9800 | AID720495 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (94)
Molecular Functions (33)
Ceullar Components (29)
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 42.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||